The posterior triangle is where the accessory nerve is located, and it is susceptible to injury in this area. In addition to experiencing issues with shoulder shrugging, the individual may also encounter challenges when attempting to raise their arm above their head.

The posterior triangle of the neck is an area that is bound by the sternocleidomastoid and trapezius muscles, the occipital bone, and the middle third of the clavicle. Within this triangle, there are various nerves, vessels, muscles, and lymph nodes. The nerves present include the accessory nerve, phrenic nerve, and three trunks of the brachial plexus, as well as branches of the cervical plexus such as the supraclavicular nerve, transverse cervical nerve, great auricular nerve, and lesser occipital nerve. The vessels found in this area are the external jugular vein and subclavian artery. Additionally, there are muscles such as the inferior belly of omohyoid and scalene, as well as lymph nodes including the supraclavicular and occipital nodes.

When there is systolic dysfunction, the ejection fraction decreases as the stroke volume decreases. However, in cases of diastolic dysfunction, ejection fraction is not a reliable indicator as both stroke volume and end-diastolic volume may be reduced. Diastolic dysfunction occurs when the heart’s compliance is reduced.

Cardiovascular physiology involves the study of the functions and processes of the heart and blood vessels. One important measure of heart function is the left ventricular ejection fraction, which is calculated by dividing the stroke volume (the amount of blood pumped out of the left ventricle with each heartbeat) by the end diastolic LV volume (the amount of blood in the left ventricle at the end of diastole) and multiplying by 100%. Another key measure is cardiac output, which is the amount of blood pumped by the heart per minute and is calculated by multiplying stroke volume by heart rate.

Pulse pressure is another important measure of cardiovascular function, which is the difference between systolic pressure (the highest pressure in the arteries during a heartbeat) and diastolic pressure (the lowest pressure in the arteries between heartbeats). Factors that can increase pulse pressure include a less compliant aorta (which can occur with age) and increased stroke volume.

Finally, systemic vascular resistance is a measure of the resistance to blood flow in the systemic circulation and is calculated by dividing mean arterial pressure (the average pressure in the arteries during a heartbeat) by cardiac output. Understanding these measures of cardiovascular function is important for diagnosing and treating cardiovascular diseases.

Patients with peripheral vascular disease may experience worsened symptoms when taking beta-blockers, and caution should be exercised when prescribing this medication. Additionally, those with Raynaud disease may also experience aggravated symptoms. Monitoring for signs of progressive arterial obstruction is recommended.

Beta-blockers are a class of drugs that are primarily used to manage cardiovascular disorders. They have a wide range of indications, including angina, post-myocardial infarction, heart failure, arrhythmias, hypertension, thyrotoxicosis, migraine prophylaxis, and anxiety. Beta-blockers were previously avoided in heart failure, but recent evidence suggests that certain beta-blockers can improve both symptoms and mortality. They have also replaced digoxin as the rate-control drug of choice in atrial fibrillation. However, their role in reducing stroke and myocardial infarction has diminished in recent years due to a lack of evidence.

Examples of beta-blockers include atenolol and propranolol, which was one of the first beta-blockers to be developed. Propranolol is lipid-soluble, which means it can cross the blood-brain barrier.

Like all drugs, beta-blockers have side-effects. These can include bronchospasm, cold peripheries, fatigue, sleep disturbances (including nightmares), and erectile dysfunction. There are also some contraindications to using beta-blockers, such as uncontrolled heart failure, asthma, sick sinus syndrome, and concurrent use with verapamil, which can precipitate severe bradycardia.

The allantois leaves behind the urachus, while the male prostatic utricle is a vestige of the vagina. The ductus arteriosus is represented by the ligamentum arteriosum, which links the aorta to the pulmonary trunk during fetal development. The ligamentum venosum, on the other hand, is the residual structure of the ductus venous, which diverts blood from the left umbilical vein to the placenta, bypassing the liver.

During cardiovascular embryology, the heart undergoes significant development and differentiation. At around 14 days gestation, the heart consists of primitive structures such as the truncus arteriosus, bulbus cordis, primitive atria, and primitive ventricle. These structures give rise to various parts of the heart, including the ascending aorta and pulmonary trunk, right ventricle, left and right atria, and majority of the left ventricle. The division of the truncus arteriosus is triggered by neural crest cell migration from the pharyngeal arches, and any issues with this migration can lead to congenital heart defects such as transposition of the great arteries or tetralogy of Fallot. Other structures derived from the primitive heart include the coronary sinus, superior vena cava, fossa ovalis, and various ligaments such as the ligamentum arteriosum and ligamentum venosum. The allantois gives rise to the urachus, while the umbilical artery becomes the medial umbilical ligaments and the umbilical vein becomes the ligamentum teres hepatis inside the falciform ligament. Overall, cardiovascular embryology is a complex process that involves the differentiation and development of various structures that ultimately form the mature heart.

For patients diagnosed with heart failure with reduced LVEF, the initial treatment should involve administering a beta blocker and an ACE inhibitor. In the case of the patient in question, the symptoms and echocardiogram results indicate the onset of LV failure, which is likely due to their previous STEMI. Therefore, the recommended course of action is to prescribe an ACE inhibitor and beta-blocker as the primary therapy. This will help alleviate the symptoms of heart failure by reducing the after-load on the heart.

Chronic heart failure can be managed through drug treatment, according to updated guidelines issued by NICE in 2018. While loop diuretics are useful in managing fluid overload, they do not reduce mortality in the long term. The first-line treatment for all patients is a combination of an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Aldosterone antagonists are recommended as second-line treatment, but potassium levels should be monitored as both ACE inhibitors and aldosterone antagonists can cause hyperkalaemia. Third-line treatment should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, and cardiac resynchronisation therapy. Other treatments include annual influenzae and one-off pneumococcal vaccines. Those with asplenia, splenic dysfunction, or chronic kidney disease may require a booster every 5 years.

The most likely diagnosis for a patient with global ST and PR segment changes is pericarditis. This condition is characterized by inflammation of the pericardium, which often occurs after a respiratory illness. Patients with pericarditis typically experience sharp chest pain that worsens with inspiration or lying down and improves when leaning forward.

While benign early repolarization (BER) can also cause ST elevation, it is less likely in this case as the patient’s symptoms are more consistent with pericarditis. Additionally, BER often presents with a fish hook pattern on the ECG.

Infective endocarditis, pulmonary embolism (PE), and myocardial infarction (MI) are less likely diagnoses. Infective endocarditis typically presents with fever and a murmur, while PE is associated with tachycardia, haemoptysis, and signs of deep vein thrombosis. MI is usually confined to a specific territory on the ECG and is unlikely in a patient with low cardiac risk factors.

Acute Pericarditis: Causes, Features, Investigations, and Management

Acute pericarditis is a possible diagnosis for patients presenting with chest pain. The condition is characterized by chest pain, which may be pleuritic and relieved by sitting forwards. Other symptoms include non-productive cough, dyspnoea, and flu-like symptoms. Tachypnoea and tachycardia may also be present, along with a pericardial rub.

The causes of acute pericarditis include viral infections, tuberculosis, uraemia, trauma, post-myocardial infarction, Dressler’s syndrome, connective tissue disease, hypothyroidism, and malignancy.

Investigations for acute pericarditis include ECG changes, which are often global/widespread, as opposed to the ‘territories’ seen in ischaemic events. The ECG may show ‘saddle-shaped’ ST elevation and PR depression, which is the most specific ECG marker for pericarditis. All patients with suspected acute pericarditis should have transthoracic echocardiography.

Management of acute pericarditis involves treating the underlying cause. A combination of NSAIDs and colchicine is now generally used as first-line treatment for patients with acute idiopathic or viral pericarditis.

In summary, acute pericarditis is a possible diagnosis for patients presenting with chest pain. The condition is characterized by chest pain, which may be pleuritic and relieved by sitting forwards, along with other symptoms. The causes of acute pericarditis are varied, and investigations include ECG changes and transthoracic echocardiography. Management involves treating the underlying cause and using a combination of NSAIDs and colchicine as first-line treatment.

The final stage of cardiac contraction, ventricular repolarization, is symbolized by the T wave. This can be easily remembered by recognizing that it occurs after the QRS complex, which represents earlier phases of contraction.

Understanding the Normal ECG

The electrocardiogram (ECG) is a diagnostic tool used to assess the electrical activity of the heart. The normal ECG consists of several waves and intervals that represent different phases of the cardiac cycle. The P wave represents atrial depolarization, while the QRS complex represents ventricular depolarization. The ST segment represents the plateau phase of the ventricular action potential, and the T wave represents ventricular repolarization. The Q-T interval represents the time for both ventricular depolarization and repolarization to occur.

The P-R interval represents the time between the onset of atrial depolarization and the onset of ventricular depolarization. The duration of the QRS complex is normally 0.06 to 0.1 seconds, while the duration of the P wave is 0.08 to 0.1 seconds. The Q-T interval ranges from 0.2 to 0.4 seconds depending upon heart rate. At high heart rates, the Q-T interval is expressed as a ‘corrected Q-T (QTc)’ by taking the Q-T interval and dividing it by the square root of the R-R interval.

Understanding the normal ECG is important for healthcare professionals to accurately interpret ECG results and diagnose cardiac conditions. By analyzing the different waves and intervals, healthcare professionals can identify abnormalities in the electrical activity of the heart and provide appropriate treatment.

When viewed under polarised light, amyloidosis exhibits a distinctive apple green birefringence.

Understanding Amyloid: Protein Deposits that Affect Tissue Structure and Function

Amyloid refers to the accumulation of insoluble protein deposits outside of cells. These deposits can disrupt the normal structure of tissues and, if excessive, can impair their function. Amyloid is composed of a major fibrillar protein that defines its type, along with various minor components. The different types of amyloid are classified with the prefix A and a suffix that corresponds to the fibrillary protein present. The two main clinical types are AA and AL amyloidosis.

Systemic AA amyloidosis is a long-term complication of several chronic inflammatory disorders, such as rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, malignancies, and conditions that predispose individuals to recurrent infections. On the other hand, AL amyloidosis results from the deposition of fibril-forming monoclonal immunoglobulin light chains, most commonly of lambda isotype, outside of cells. Most patients with AL amyloidosis have evidence of isolated monoclonal gammopathy or asymptomatic myeloma, and the occurrence of AL amyloidosis in patients with symptomatic multiple myeloma or other B-cell lymphoproliferative disorders is unusual. The kidney and heart are two of the most commonly affected sites.

Diagnosis of amyloidosis is based on surgical biopsy and characteristic histological features, which consist of birefringence under polarised light. Immunohistochemistry is used to determine the subtype. Treatment is usually targeted at the underlying cause. Understanding amyloid and its different types is crucial in the diagnosis and management of patients with amyloidosis.

ST elevation is expected in the leads corresponding to the affected part of the heart in an STEMI, while ST depression, T wave inversion, or no change is expected in an NSTEMI or angina. Dilated cardiomyopathy does not have any classical ECG changes, and it is not commonly associated with hypertension as LVF. LVF, on the other hand, causes left ventricular hypertrophy due to prolonged hypertension, resulting in an increase in R-wave amplitude in leads 1, aVL, and V4-6, as well as an increase in S wave depth in leads III, aVR, and V1-3 on the right side.

ECG Indicators of Atrial and Ventricular Hypertrophy

Left ventricular hypertrophy is indicated on an ECG when the sum of the S wave in V1 and the R wave in V5 or V6 exceeds 40 mm. Meanwhile, right ventricular hypertrophy is characterized by a dominant R wave in V1 and a deep S wave in V6. In terms of atrial hypertrophy, left atrial enlargement is indicated by a bifid P wave in lead II with a duration of more than 120 ms, as well as a negative terminal portion in the P wave in V1. On the other hand, right atrial enlargement is characterized by tall P waves in both II and V1 that exceed 0.25 mV. These ECG indicators can help diagnose and monitor patients with atrial and ventricular hypertrophy.

Patients with pulmonary embolism may exhibit sinus tachycardia as the most common ECG sign, as well as signs of right heart strain rather than left.

Pulmonary embolism can be difficult to diagnose as it can present with a variety of cardiorespiratory symptoms and signs depending on its location and size. The PIOPED study in 2007 found that tachypnea, crackles, tachycardia, and fever were common clinical signs in patients diagnosed with pulmonary embolism. The Well’s criteria for diagnosing a PE use tachycardia rather than tachypnea. All patients with symptoms or signs suggestive of a PE should have a history taken, examination performed, and a chest x-ray to exclude other pathology.

To rule out a PE, the pulmonary embolism rule-out criteria (PERC) can be used. All criteria must be absent to have a negative PERC result, which reduces the probability of PE to less than 2%. If the suspicion of PE is greater than this, a 2-level PE Wells score should be performed. A score of more than 4 points indicates a likely PE, and an immediate computed tomography pulmonary angiogram (CTPA) should be arranged. If the CTPA is negative, patients do not need further investigations or treatment for PE.

CTPA is now the recommended initial lung-imaging modality for non-massive PE. V/Q scanning may be used initially if appropriate facilities exist, the chest x-ray is normal, and there is no significant symptomatic concurrent cardiopulmonary disease. D-dimer levels should be considered for patients over 50 years old. A chest x-ray is recommended for all patients to exclude other pathology, but it is typically normal in PE. The sensitivity of V/Q scanning is around 75%, while the specificity is 97%. Peripheral emboli affecting subsegmental arteries may be missed on CTPA.